Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")

Main Inclusion Criteria: * Female patient 18 to 75 years old diagnosed with idiopathic OAB. * Patient has symptoms of OAB for ≥ 3 months prior to screening. * Patient is a non-responder to pharmacologic therapy or has intolerable side effects or is not compliant to the treatment. * On screening three-day voiding diary- Patient has a frequency of at least 8 micturitions per 24 hours \& Total of ≥3 urgency urinary incontinence (UUI) episodes. * Patient is willing and able to initiate self catheterization post-treatment, if required. * Patients has PVR ≤100 ml. Patient with a single PVR of \>100 ml and followed by two consecutive PVR measurements of \<100 ml may be included in the study). Main Exclusion Criteria: * Patient currently uses CIC or indwelling catheter to manage their urinary incontinence * Patient who has clinically significant Bladder Outlet Obstruction (BOO). * Patient with active urinary tract infection. * OAB due to any known neurological reason. * Patient with 24-hour total urine volume voided greater than 3,000 ml as measured at screening visit. * Predominance of stress incontinence in the opinion of the investigator, determined by patient history. * Use of anticholinergics or other medications or therapies to treat symptoms of OAB within 7 days of screening. * Patient with prior botulinum toxin therapy of any serotype within 12 weeks for any indication. * Patient with prior use of Botulinum toxin therapy of any serotype for any urological condition. * Patient with previous pelvic radiation therapy. * Patient had been treated for two or more UTIs within last 6 months or use of prophylactic antibiotics to prevent chronic UTIs. * ANY condition identified which may cause overactive bladder symptoms